# Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer

Source: https://onco.cc/trials/nct04665856/  
OnCo record `nct04665856` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Tiragolumab, Atezolizumab, Carboplatin and Etoposide in small-cell lung cancer, run by Hoffmann-La Roche, now completed.

## Summary

Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer is a phase 3 interventional study registered as NCT04665856 by Hoffmann-La Roche, with 123 participants enrolled, started 2020-12-21 and reached its primary completion in 2023-08-31. Interventions recorded: Tiragolumab, Atezolizumab, Carboplatin, Etoposide and Tiragolumab Matching Placebo. Results have been posted on the registry.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-09-22
- Also known as: SKYSCRAPER-02C
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04665856
- Phase: 3
- Setting: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer
- Sponsor: Hoffmann-La Roche
- Enrolled: 123
- Outcomes: Investigator-assessed Progression-free Survival (PFS) in the Primary Analysis Set (PAS): Placebo + Atezolizumab + Carboplatin + Etoposide 5.39 months vs Tiragolumab + Atezolizumab + Carboplatin + Etoposide 5.59 months, HR 0.65; Overall Survival (OS) in the PAS: Placebo + Atezolizumab + Carboplatin + Etoposide 13.54 months vs Tiragolumab + Atezolizumab + Carboplatin + Etoposide 18.69 months, HR 0.89; Investigator-assessed Confirmed Objective Response Rate (ORR) in the PAS: Placebo + Atezolizumab + Carboplatin + Etoposide 58.9% vs Tiragolumab + Atezolizumab + Carboplatin + Etoposide 81.5%

## Notes

- Registry status on 22 September 2026: Completed (registry record last updated 18 September 2026; primary completion reached 31 August 2023).

## Sources

- ClinicalTrials.gov NCT04665856: https://clinicaltrials.gov/study/NCT04665856

## Connected records

- cancers: [Extensive-stage small-cell lung cancer](https://onco.cc/cancers/extensive-stage-sclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [Platinum agents](https://onco.cc/technologies/platinum/), [TIGIT blockade](https://onco.cc/technologies/tigit-blockade/), [Topoisomerase-I inhibitors (and ADC payloads)](https://onco.cc/technologies/topoisomerase-inhibitors/)
- drugs: [Atezolizumab](https://onco.cc/drugs/atezolizumab/), [Carboplatin](https://onco.cc/drugs/carboplatin/), [Etoposide](https://onco.cc/drugs/etoposide/), [Tiragolumab](https://onco.cc/drugs/tiragolumab/)
- companies: [Flatiron Health (Roche)](https://onco.cc/companies/flatiron-health/)
- key papers: [SKYSCRAPER-02C: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage SCLC in China](https://onco.cc/key-papers/paper-nct04665856-j-thorac-oncol-2026/)

---
JSON: https://onco.cc/api/v1/entities/nct04665856.json